Observational Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022 and HZ Efficacy, Immunogenicity and Safety of HZ/su by Frailty Status
Latest Information Update: 05 Sep 2023
At a glance
- Drugs GSK 137173A (Primary)
- Indications Herpes zoster
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 30 May 2019 Status changed from recruiting to completed.
- 28 Jun 2018 New trial record